Sebacia, Inc., a Duluth, Georgia-based clinical-stage medical device company dedicated to the treatment of dermatological conditions, received a $10m credit facility.
Square 1 Bank provided the debt financing.
The company intends to use the funds for continued growth, including completing a pivotal U.S. clinical trial to support FDA approval of its treatment for moderate to severe acne, expanding intellectual property portfolio, as well as preparing for manufacturing scale-up to support European and U.S. launches of the product.
Founded in 2010 and led by Anthony Lando, chief executive officer, Sebacia is committed to the treatment of acne through new light-based treatments and procedures. The treatment uses microparticles in combination with hair removal lasers to treat targeted areas affected by acne.